Caring Ambassadors Hepatitis C Program Newsletter

www.HepCChallenge.org

October 2010

Check out - Liver Cancer - NEW CATEGORY THIS MONTH!

Clinical Trials, Cohort Studies, Pilot Studies

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.

Mauss S, Hueppe D, John C, et al. J Viral Hepat. 2010 Sep 16. doi: 10.1111/j.1365-2893.2010.01372.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20849436

Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Manolakopoulos S, Deutsch MJ, Anagnostou O, et al. Liver Int. 2010 Sep 16. doi: 10.1111/j.1478-3231.2010.02341.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20846344

Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Melin P, Chousterman M, Fontanges T, et al. Eur J Gastroenterol Hepatol. 2010 Sep;22(9):1050-7.

http://www.ncbi.nlm.nih.gov/pubmed/20351554

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Muir AJ, Shiffman ML, Zaman A, et al. Hepatology. 2010 Sep;52(3):822-32.

http://www.ncbi.nlm.nih.gov/pubmed/20564352

Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. Liu SS, Schneekloth TD, Talwalkar JA, et al. J Clin Gastroenterol. 2010 Sep;44(8):e178-85.

http://www.ncbi.nlm.nih.gov/pubmed/20495464

Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Moucari R, Forestier N, Larrey D, et al. Gut. 2010 Sep 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20861007

Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Morgan TR, Ghany MG, Kim HY, et al. Hepatology. 2010 Sep;52(3):833-44.

http://www.ncbi.nlm.nih.gov/pubmed/20564351

Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. Kurosaki M, Sakamoto N, Iwasaki M, et al. J Gastroenterol. 2010 Sep 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20830599

Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Rao GA, Pandya PK. Gastroenterology. 2010 Sep 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20833169

An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C. Tinè F, Graviano D, Giannuoli G, et al. Pharmacoepidemiol Drug Saf. 2010 Sep 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20848397

Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more. Giannini EG, Basso M, Savarino V, Picciotto A. Dig Dis Sci. 2010 Sep 18. [Epub ahead of print] Dig Dis Sci. 2010 Sep 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20848200

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Morasco BJ, Loftis JM, Indest DW, et al. Psychosomatics. 2010 Sep-Oct;51(5):401-8.

http://www.ncbi.nlm.nih.gov/pubmed/20833939

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Harrison SA, Rossaro L, Hu KQ, et al. Hepatology. 2010 Sep;52(3):864-74.

78234, USA. stephen.harrison@amedd.army.mil

http://www.ncbi.nlm.nih.gov/pubmed/20568303

Associations between serum lipids and hepatitis C antiviral treatment efficacy. Ramcharran D, Wahed AS, Conjeevaram HS, et al. Hepatology. 2010 Sep;52(3):854-63.

http://www.ncbi.nlm.nih.gov/pubmed/20690192

Basic and Applied Science, Pre-Clinical Studies

Hepatitis C virus induces the cannabinoid receptor 1. van der Poorten D, Shahidi M, Tay E, et al. PLoS One. 2010 Sep 17;5(9). pii: e12841.

http://www.ncbi.nlm.nih.gov/pubmed/20862263

Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C virus infection. Sugalski JM, Rodriguez B, Moir S, Anthony DD. J Immunol. 2010 Sep 1;185(5): 3019-27. Epub 2010 Jul 23.

http://www.ncbi.nlm.nih.gov/pubmed/20656924

Quantitative analysis of interferon alpha receptor subunit 1 and suppressor of cytokine signaling 1 gene transcription in blood cells of patients with chronic hepatitis C.

Sedeno-Monge V, Santos-Lopez G, Rocha-Gracia RC, et al. Virol J. 2010 Sep 18;7(1):243. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20849643

A novel small molecule inhibitor of hepatitis C virus entry. Baldick CJ, Wichroski MJ, Pendri A, et al. LoS Pathog. 2010 Sep 2;6(9). pii: e1001086.

http://www.ncbi.nlm.nih.gov/pubmed/20838466

Association of serum adipocytokines with hepatic steatosis and fibrosis in patients with chronic hepatitis C. Baranova A, Jarrar MH, Stepanova M, et al. Digestion. 2010 Sep 15;83(1-2):32-40. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20847561

HIV/HCV/HBV Coinfection

Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir through concentrations in HIV-infected patients. Calza L, Mosca L, Pocaterra D, et al. Eur J Clin Pharmacol. 2010 Sep 28. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20878151

Proteome-wide anti-hepatitis C virus (HCV) and anti-HIV antibody profiling for predicting and monitoring the response to HCV therapy in HIV-coinfected patients.

Burbelo PD, Kovacs JA, Ching KH, et al. J Infect Dis. 2010 Sep 15;202(6):894-8.

http://www.ncbi.nlm.nih.gov/pubmed/20684729

Serological and molecular expression of hepatitis b infection in patients with chronic hepatitis C from Tunisia, North Africa. Ben Halima S, Bahri O, Maamouri N, et al. Virol J. 2010 Sep 15;7(1):229. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20843308

Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. Chary A, Winters MA, Kottilil S, et al. J Infect Dis. 2010 Sep 15;202(6):889-93.

http://www.ncbi.nlm.nih.gov/pubmed/20677940

Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Genebat M, Ruiz-Mateos E, Pulido I, et al. Curr HIV Res. 2010 Sep 1;8(6):482-6.

http://www.ncbi.nlm.nih.gov/pubmed/20642436

Hepatitis C virus core protein induces neuroimmune activation and potentiates human immunodeficiency virus-1 neurotoxicity. Vivithanaporn P, Maingat F, Lin LT, et al. PLoS One. 2010 Sep 21;5(9). pii: e12856.

http://www.ncbi.nlm.nih.gov/pubmed/20877724

Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Int J Infect Dis. 2010 Sep 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20870439

Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients. Reuter S, Oette M, Wilhelm FC, et al. Med Microbiol Immunol. 2010 Sep 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20853118

Elevated TGF-β1 levels might protect HCV/ HIV-coinfected patients from liver fibrosis.

Rallón NI, Barreiro P, Soriano V, et al. Eur J Clin Invest. 2010 Sep 27. doi: 10.1111/j.1365-2362.2010.02381.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20868448

Complementary and Alternative Medicine

S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Feld JJ, Modi AA, El-Diwany R, et al. Gastroenterology. 2010 Sep 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20854821

Epidemiology, Diagnostics, and Miscellaneous Works

Validation of Biochemical Markers for the Prediction of Liver Fibrosis and Necro-inflammatory Activity in Hemodialysis Patients with Chronic Hepatitis C.

Canbakan M, Senturk H, Canbakan B, et al. Nephron Clin Pract. 2010 Sep 18;117(3):c289-c295. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20847572

Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. Malik R, Lai M, Sadiq A, et al. J Gastroenterol Hepatol. 2010 Sep;25(9):1562-8.

http://www.ncbi.nlm.nih.gov/pubmed/20796156

Selective atrophy of the middle hepatic venous drainage area in hepatitis c-related cirrhotic liver: Morphometric Study by Using Multidetector CT. Ozaki K, Matsui O, Kobayashi S, et al. Radiology. 2010 Sep 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20843994

End-stage liver disease: challenges and practice implications. Hansen L, Sasaki A, Zucker B. Nurs Clin North Am. 2010 Sep;45(3):411-26.

http://www.ncbi.nlm.nih.gov/pubmed/20804886

Diagnosis of occult hepatitis C without the need for a liver biopsy. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. J Med Virol. 2010 Sep;82(9):1554-9.

http://www.ncbi.nlm.nih.gov/pubmed/20648609

Hepatitis C virus genotyping using an oligonucleotide microarray based on the NS5B sequence. Gryadunov D, Nicot F, Dubois M, et al. J Clin Microbiol. 2010 Sep 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20844214

Use of gloves and reduction of risk of injury caused by needles or sharp medical devices in healthcare workers: results from a case-crossover study. Kinlin LM, Mittleman MA, Harris AD, Rubin MA, Fisman DN. Infect Control Hosp Epidemiol. 2010 Sep;31(9):908-17.

http://www.ncbi.nlm.nih.gov/pubmed/20658920

Diagnosis and management of interstitial pneumonitis associated with interferon therapy for chronic hepatitis C. Ji FP, Li ZX, Deng H, Xue HA, Liu Y, Li M.  World J Gastroenterol. 2010 Sep 21;16(35):4394-9.

http://www.ncbi.nlm.nih.gov/pubmed/20845505

Expanding access to hepatitis C virus treatment--Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. Arora S, Kalishman S, Thornton K, et al. Hepatology. 2010 Sep;52(3):1124-33.

http://www.ncbi.nlm.nih.gov/pubmed/20607688

Comparing respondent-driven sampling and targeted sampling methods of recruiting injection drug users in San Francisco. Kral AH, Malekinejad M, Vaudrey J, et al. J Urban Health. 2010 Sep;87(5):839-50.

http://www.ncbi.nlm.nih.gov/pubmed/20582573

Liver Cancer

Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. Thomas MB, Jaffe D, Choti MM, et al. J Clin Oncol. 2010 Sep 1;28(25):3994-4005. Epub 2010 Aug 2.

http://www.ncbi.nlm.nih.gov/pubmed/20679622

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer. Ikeda K, Kobayashi M, Seko Y, et al. Hepatol Res. 2010 Sep 16. doi: 10.1111/j.1872-034X.2010.00720.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20849431

Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. Kuroda H, Ushio A, Miyamoto Y, et al. J Gastroenterol Hepatol. 2010 Sep;25(9):1550-5.

http://www.ncbi.nlm.nih.gov/pubmed/20796154

Survival rates are comparable following radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Hung HH, Chiou YY, Hsia CY, et al. Clin Gastroenterol Hepatol. 2010 Sep 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20831902

Population-based risk factors and resource utilization for HCC: US perspective. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Curr Med Res Opin. 2010 Sep;26(9):2183-91.

http://www.ncbi.nlm.nih.gov/pubmed/20666689

Effects of preceding interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma.

Tomimaru Y, Nagano H, Eguchi H, et al. J Surg Oncol. 2010 Sep 15;102(4):308-14.

http://www.ncbi.nlm.nih.gov/pubmed/20589711

Cirrhosis is Present in Most Patients with Hepatitis B and Hepatocellular Carcinoma.

Yang JD, Kim WR, Coelho R, et al. Clin Gastroenterol Hepatol. 2010 Sep 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/20831903